SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Th1 cytokine patterns in cervical human papillomavirus infection.

By Leave a Comment

PubMed.gov

Clin Diagn Lab Immunol. 1999 Sep;6(5):751-5.

Scott M, Stites DP, Moscicki AB.

Department of Pediatrics, University of California, San Francisco, California 94143, USA. mscott@itsa.ucsf.edu
Abstract

The host’s immune response to cervical human papillomavirus (HPV) infection is poorly understood. In a longitudinal cohort of women with cervical HPV infections, defined by PCR-based HPV DNA testing, we used exfoliated cervical cells and reverse transcription-PCR to examine the cervical mucosal mRNA expression of cytokines involved in regulating cell-mediated immunity. We identified seven HPV-positive subjects who were found to have cleared their HPV infections 4 months later. In all seven, a T-helper type 1 (Th1) cytokine pattern (expression of gamma interferon and absence of interleukin-4) preceded clearance. The more variable cytokine patterns seen in HPV-negative subjects suggest that the Th1 pattern in the women with subsequent clearance was a response to the HPV infection.

What Really Went Wrong with Gardasil

By Leave a Comment

SEO Press Releases

North Hollywood, CA, September 10, 2010 — On September 7, 2010, Shelly Dubois wrote an article for Fortune – on CNNMoney.com, titled: What’s Wrong with Gardasil. SANE Vax.org believes that the article discredits the thousands of families, who have suffered deaths and adverse injuries to their daughters in the name of financial numbers and award-winning marketing strategies.

The article opens with: “There’s a liquid drug that women can get injected into a layer of muscle — three separate times over a six-month period — that can protect them from a kind of cancer. From a scientific perspective, that’s amazing. In terms of public health, it’s a breakthrough.

“But four years after Merck (MRK, Fortune 500) released this would-be top-seller, called Gardasil, it has proven to be a marketplace dud. In Merck’s second quarter, the company reported an 18% year-over-year drop in sales to $219 million and its stock is down nearly 3% to date. Analysts are pointing to Gardasil not as a savior, but as a risk for investors.”

Schoolgirl chlamydia increase blamed on cancer jab

By 1 Comment

Deadline Scotland

By Martin Graham

CHLAMYDIA is on the rise among Scottish schoolgirls, and the increase has been blamed on a new jab to prevent cervical cancer.

Figures released by the NHS show that cases of the sexually transmitted disease in girls under 15 have risen by over a third, with doctors treating almost two new cases of the infection every week, mostly girls who fall within the age group offered the jab.

The trend matches the timing of the introduction of the human papillomavirus (HPV) jab for all girls aged between 12 and 17 in September 2008.

Irish Mothers Unite to Stop HPV Vaccine Assault on Their Children

By 2 Comments

SEO Press Releases

North Hollywood, CA, September 7, 2010 — The Mothers’ Alliance Ireland (MAI), a committee of Christian Democrats the Family First Party dedicated to protecting the rights of parents and the welfare of children, has spent almost a decade researching the HPV/cervical cancer link and is now actively protesting mandatory vaccination of adolescent girls. MAI and concerned mothers from various counties throughout Ireland have written letters to the media, passed out information leaflets, held public meetings and contacted public health officials and politicians protesting this legislation.

Although Ireland has historically been a country filled with political strife, when it comes to the health and safety of their children, Irish mothers set aside all political differences. That is just what is happening all across the country – concerned mothers and political activists have united to call a halt to the Irish HPV vaccination programme.

What went wrong with Gardasil

By Leave a Comment

CNN Money
September 7, 2010

FORTUNE — There’s a liquid drug that women can get injected into a layer of muscle — three separate times over a six-month period — that can protect them from a kind of cancer. From a scientific perspective, that’s amazing. In terms of public health, it’s a breakthrough.

But four years after Merck (MRK, Fortune 500) released this would-be top-seller, called Gardasil, it has proven to be a marketplace dud. In Merck’s second quarter, the company reported an 18% year-over-year drop in sales to $219 million and its stock is down nearly 3% to date. Analysts are pointing to Gardasil not as a savior, but as a risk for investors.

News

Videos

Contact